Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase II Trials
Retrieved on:
星期二, 四月 2, 2024
Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate U.S.
Key Points:
- Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate U.S.
- Phase II masked, randomized clinical trials investigating QLS‑111 in patients with ocular hypertension and glaucoma.
- “The start of these Phase II trials represents a key milestone in our goal of bringing QLS‑111 to glaucoma patients for whom consistent IOP lowering and control has been an unachievable goal,” said Thurein Htoo, Chief Executive Officer.
- “IOP remains the only modifiable risk factor for the treatment of glaucoma, and additional treatments are needed for patients.